Physiologically-based pharmacokinetics in drug development and regulatory science

Annual Review of Pharmacology and Toxicology

Volumn 51, Issue , 2011, Pages 45-73

  Rowland, Malcolm ^a   Peck, Carl ^b   Tucker, Geoffrey ^c,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d CERTARA UK LIMITED   (United Kingdom)

Author keywords

drug regulation; industrial; mechanistic; modeling; simulation

Indexed keywords

ALFENTANIL; ASTEMIZOLE; CAFFEINE; CERIVASTATIN; CIMETIDINE; CISAPRIDE; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2C9; DICLOFENAC; DOFETILIDE; DRUG METABOLIZING ENZYME; ETIRACETAM; GLUCURONOSYLTRANSFERASE; LEVACETYLMETHADOL; LIDOCAINE; METOPROLOL; MIBEFRADIL; MIDAZOLAM; NIFEDIPINE; OMEPRAZOLE; PAROXETINE; QUINIDINE; SILDENAFIL; TAMOXIFEN; TERFENADINE; THEOPHYLLINE; WARFARIN;

AGE; ALLOMETRY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BREAST CANCER; DRUG ABSORPTION; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG DESIGN; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INTERACTION; DRUG LEGISLATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; ENZYME INHIBITION; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART REINFARCTION; HUMAN; IN VITRO STUDY; INFLAMMATION; INTERMETHOD COMPARISON; KIDNEY DISEASE; LIVER CELL; LIVER CLEARANCE; LIVER DYSFUNCTION; LIVER MICROSOME; MONTE CARLO METHOD; NONHUMAN; PHARMACOGENETICS; PHARMACOKINETICS; PHYSIOLOGICALLY BASED PHARMACOKINETICS; PRIORITY JOURNAL; QT PROLONGATION; RHABDOMYOLYSIS; TORSADE DES POINTES;

ANIMALS; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; DRUG DESIGN; DRUG INTERACTIONS; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 79951765993     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010510-100540     Document Type: Article

References (198)

1. Teorell T. 1937. Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration. Arch. Int. Pharmacodyn. Ther. 57:202-5
2. Grasela TH, Dement CW, Kolterman OG, Fineman MS, Grasela DM, et al. 2007. Pharmacometrics and the transition to model-based development. Clin. Pharmacol. Ther. 82:137-42 (Pubitemid 47075347)
3. Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, et al. 2007. Model-based drug development. Clin. Pharmacol. Ther. 82:21-32 (Pubitemid 46950619)
4. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3:711-15 (Pubitemid 39173511)
5. Harrison LI, Gibaldi M. 1977. Physiologically based pharmacokinetic model for digoxin disposition in dogs and its preliminary application to humans. J. Pharm. Sci. 66:1679-83 (Pubitemid 8246673)
6. Papper EM, Kitz RJ. 1963. Uptake and Distribution of Anesthetic Agents. New York: McGraw-Hill. 321 pp.
7. Benowitz N, Forsyth RP, Melmon KL, Rowland M. 1974. Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model. Clin. Pharmacol. Ther. 16:87-98
8. Bischoff KB, Dedrick RL. 1968. Thiopental pharmacokinetics. J. Pharm. Sci. 57:1346-51
9. Lin JH, Sugiyama Y, Awazu S, Hanano M. 1982. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J. Pharmacokinet. Biopharm. 10:649-61 (Pubitemid 13112144)
10. Edginton AN, Theil FP, Schmitt W, Willmann S. 2008. Whole body physiologically-based pharma-cokinetic models: their use in clinical drug development. Expert Opin. Drug Metab. Toxicol. 4:1143-52
11. Lave T, Parrott N, Grimm HP, Fleury A, Reddy M. 2007. Challenges and opportunities with modeling and simulation in drug discovery and drug development. Xenobiotica 37:1295-310 (Pubitemid 350035528)
12. Theil FP, Guentert TW, Haddad S, Poulin P. 2003. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol. Lett. 138:29-49 (Pubitemid 36142054)
13. Nestorov I. 2003. Whole body pharmacokinetic models. Clin. Pharmacokinet. 42:883-908 (Pubitemid 36995260)
14. Nestorov I. 2007. Whole-body physiologically based pharmacokinetic models. Expert Opin. Drug Metab. Toxicol. 3:235-49 (Pubitemid 47321518)
15. Poulin P, Theil FP. 2002. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J. Pharm. Sci. 91:1358-70 (Pubitemid 34651198)
16. Thompson CM, Sonawane B, Barton HA, DeWoskin RS, Lipscomb JC, et al. 2008. Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J. Toxicol. Environ. Health B 11:519-47 (Pubitemid 351940844)
17. Reddy M, Yang RS, Andersen ME, Clewell HJ III. 2005. Physiologically Based Pharmacokinetic Modeling: Science and Applications. New York: Wiley. 420 pp.
18. Rowland M, Balant L, Peck C. 2004. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPS J. 6:56-67
19. Davda JP, Jain M, Batra SK, Gwilt PR, Robinson DH. 2008. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int. Immunopharmacol. 8:401-13 (Pubitemid 351221431)
20. Fang LY, Sun DX. 2008. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy. Drug Metab. Dispos. 36:1153-65
21. Thygesen P, Macheras P, Van Peer A. 2009. Physiologically-based PK/PD modeling of therapeutic macromolecules. Pharm. Res. 26:2543-50
22. Wang W, Wang EQ, Balthasar JP. 2008. Monoclonal antibody pharmacokinetics and pharmacodynam-ics. Clin. Pharmacol. Ther. 84:548-58
23. Lowe PJ. 2010. Applying physiological and biochemical concepts to optimize biological drug development. Clin. Pharmacol. Ther. 87:492-96
24. Oliver RE, Jones AF, Rowland M. 2001. A whole-body physiologically based pharmacokinetic model incorporating dispersion concepts: short and long time characteristics. J. Pharmacokinet. Pharmacodyn. 28:27-55
25. Upton RN, Grant C, Martinez AM, Ludbrook GL. 2004. Recirculatory model of fentanyl disposition with the brain as the target organ. Br. J. Anaesth. 93:687-97 (Pubitemid 39445551)
26. Upton RN, Ludbrook G. 2005. A physiologically based, recirculatory model of the kinetics and dynamics of propofol in man. Anesthesiology 103:344-52 (Pubitemid 41076732)
27. Karalis V, Dokoumetzidis A, Macheras P. 2004. A physiologically based approach for the estimation of recirculatory parameters. J. Pharmacol. Exp. Ther. 308:198-205 (Pubitemid 38090718)
28. Dokoumetzidis A, Aarons L. 2009. A method for robust model order reduction in pharmacokinetics. J. Pharmacokinet. Pharmacodyn. 36:613-28
29. Gueorguieva I, Nestorov IA, Rowland M. 2006. Reducing whole body physiologically based pharma-cokinetic models using global sensitivity analysis: diazepam case study. J. Pharmacokinet. Pharmacodyn. 33:1-27
30. Lupfert C, Reichel A. 2005. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery. Chem. Biodivers. 2:1462-86 (Pubitemid 41762899)
31. Parrott N, Lave T. 2008. Applications of physiologically based absorption models in drug discovery and development. Mol. Pharm. 5:760-75
32. Rostami-Hodjegan A, Tucker GT. 2007. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 6:140-48 (Pubitemid 46745341)
33. Espie P, Tytgat D, Sargentini-Maier ML, Poggesi I, Watelet JB. 2009. Physiologically based pharma-cokinetics (PBPK). Drug Metab. Rev. 41:391-407
34. Jones HM, Gardner IB, Watson KJ. 2009. Modeling and PBPK simulation in drug discovery. AAPS J. 11:155-66
35. Brightman FA, Leahy DE, Searle GE, Thomas S. 2006. Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. Drug Metab. Dispos. 34:94-101 (Pubitemid 43042650)
36. Leahy DE. 2006. Integrating in vitro ADMET data through generic physiologically based pharmacoki-netic models. Expert Opin. Drug Metab. Toxicol. 2:619-28
37. Poirier A, Cascais AC, Funk C, Lave T. 2009. Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. Chem. Biodivers. 6:1975-87
38. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. 2009. Physiologically based pharmacoki-netic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther. 328:652-62
39. Kawai R, Mathew D, Tanaka C, Rowland M. 1998. Physiologically based pharmacokinetics of Cy-closporine A: extension to tissue distribution kinetics in rats and scale-up to human. J. Pharmacol. Exp. Ther. 287:457-68 (Pubitemid 29133641)
40. Fenneteau F, Li J, Nekka F. 2009. Assessing drug distribution in tissues expressing P-glycoprotein using physiologically based pharmacokinetic modeling: identification of important model parameters through global sensitivity analysis. J. Pharmacokinet. Pharmacodyn. 36:495-522
41. Huang W, Lee SL, Yu LX. 2009. Mechanistic approaches to predicting oral drug absorption. AAPS J. 11:217-24
42. Sugano K. 2009. Introduction to computational oral absorption simulation. Expert Opin. Drug Metab. Toxicol. 5:259-93
43. Yu LX, Amidon GL. 1999. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm. 186:119-25 (Pubitemid 29459038)
44. Agoram B, Woltosz WS, Bolger MB. 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50:S41-67 (Pubitemid 32905355)
45. Jamei M, Turner D, Yang JS, Neuhoff S, Polak S, et al. 2009. Population-based mechanistic prediction of oral drug absorption. AAPS J. 11:225-37
46. Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman JB. 2004. A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 47:4022-31 (Pubitemid 38970963)
47. McCarley KD, Bunge AL. 2001. Pharmacokinetic models of dermal absorption. J. Pharm. Sci. 90:1699-719 (Pubitemid 33062591)
48. Avram MJ, Henthorn TK, Spyker DA, Krejcie TC, Lloyd PM, etal. 2007. Recirculatory pharmacokinetic model of the uptake, distribution, and bioavailability of prochlorperazine administered as a thermally generated aerosol in a single breath to dogs. Drug Metab. Dispos. 35:262-67 (Pubitemid 46148739)
49. Liu XR, Smith BJ, Chen CP, Callegari E, Becker SL, et al. 2005. Use of a physiologically based phar-macokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J. Pharmacol. Exp. Ther. 313:1254-62 (Pubitemid 40727030)
50. Modok S, Hyde P, Mellor HR, Roose T, Callaghan R. 2006. Diffusivity and distribution of vinblastine in three-dimensional tumour tissue: experimental and mathematical modeling. Eur. J. Cancer 42:2404-13 (Pubitemid 44316902)
51. Pang KS, Maeng HJ, Fan JH. 2009. Interplay of transporters and enzymes in drug and metabolite processing. Mol. Pharm. 6:1734-55
52. Jamei M, Dickinson GL, Rostami-Hodjegan A. 2009. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs. 'top-down' recognition of covariates. Drug Metab. Pharmacokinet. 24:53-75
53. Price PS, Conolly RB, Chaisson CF, Gross EA, Young JS, et al. 2003. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 33:469-503 (Pubitemid 37268185)
54. Willmann S, Hohn K, Edginton A, Sevestre M, Solodenko J, et al. 2007. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharma-cokinetics of drugs. J. Pharmacokinet. Pharmacodyn. 34:401-31 (Pubitemid 46873033)
55. Polasek TM, Polak S, Doogue MP, Rostami-Hodjegan A, Miners JO. 2009. Assessment of inter-individual variability in predicted phenytoin clearance. Eur. J. Clin. Pharmacol. 65:1203-10
56. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23:3-25 (Pubitemid 27046991)
57. Rodgers T, Rowland M. 2006. Physiologically based pharmacokinetic modeling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 95:1238-57 (Pubitemid 43874439)
58. Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. 2002. The influence of nonspecific micro-somal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab. Dispos. 30:1497-503 (Pubitemid 35397059)
59. Hallifax D, Houston JB. 2006. Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab. Dispos. 34:724-27
60. Turner D, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. 2006. Prediction of non-specific hepatic microsomal binding from readily available physicochemical properties. Drug Metab. Rev. 38:162 (Abstr.)
61. Tang HD, Mayersohn M. 2006. A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J. Pharm. Sci. 95:1783-99 (Pubitemid 44229585)
62. Wajima T, Yano Y, Fukumura K, Oguma T. 2004. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J. Pharm. Sci. 93:1890-1900 (Pubitemid 38823714)
63. Maguire TJ, Novik E, Chao P, Barminko J, Nahmias Y, et al. 2009. Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates. Curr. Drug Metab. 10:1192-99
64. Schuhmacher J, Kohlsdorfer C, Buhner K, Brandenburger T, Kruk R. 2004. High-throughput determination of the free fraction of drugs strongly bound to plasma proteins. J. Pharm. Sci. 93:816-30 (Pubitemid 38420394)
65. Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. 2009. Utilization of estimated physico-chemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: impact of plasma and microsomal binding. Xenobiotica 39:227-35
66. Lappin G, Garner RC. 2008. The utility of microdosing over the past 5 years. Expert Opin. Drug Metab. Toxicol. 4:1499-506
67. Lave T, Chapman K, Goldsmith P, Rowland M. 2009. Human clearance prediction: shifting the paradigm. Expert Opin. Drug Metab. Toxicol. 5:1039-48
68. Chiba M, Ishii Y, Sugiyama Y. 2009. Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J. 11:262-76
69. Rane A, Wilkinson GR, Shand DG. 1977. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J. Pharmacol. Exp. Ther. 200:420-24 (Pubitemid 8037500)
70. Houston JB. 1994. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47:1469-79 (Pubitemid 24167255)
71. Roberts MS, Rowland M. 1986. A dispersion model of hepatic elimination: 2. Steady-state considerations-influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity. J. Pharmacokinet. Pharmacodyn. 14:261-88 (Pubitemid 16028175)
72. Houston JB, Galetin A. 2008. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr. Drug Metab. 9:940-51
73. Hallifax D, Houston JB. 2009. Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro experimental systems. Curr. Drug Metab. 10:307-21
74. Riley RJ, McGinnity DF, Austin RP. 2005. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab. Dispos. 33:1304-11 (Pubitemid 41196973)
75. Howgate EM, Rowland-Yeo K, Proctor NJ, Tucker GT, Rostami-Hodjegan A. 2006. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica 36:473-97 (Pubitemid 43890728)
76. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, et al. 2007. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 8:33-45 (Pubitemid 46043890)
77. Rowland A, Knights KM, Mackenzie PI, Miners JO. 2008. The "albumin effect" and drug glucuronida-tion: Bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab. Dispos. 36:1056-62 (Pubitemid 351717462)
78. Blanchard N, Richert L, Notter B, Delobel F, David P, et al. 2004. Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. Eur. J. Pharm. Sci. 23:189-99
79. Paine SW, Parker AJ, Gardiner P, Webborn PJH, Riley RJ. 2008. Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab. Dispos. 36:1365-74 (Pubitemid 351929321)
80. Poirier A, Cascais AC, Funk C, Lave T. 2009. Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J. Pharmacokinet. Pharmacodyn. 36:585-611
81. Webborn PJ, Parker AJ, Denton RL, Riley RJ. 2007. In vitro-in vivo extrapolation of hepatic clearance involving active uptake: theoretical and experimental aspects. Xenobiotica 37:1090-109 (Pubitemid 350035538)
82. Kusuhara H, Sugiyama Y. 2010. Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters. Drug Metab. Rev. 42:539-50
83. Poirier A, Lave T, Portmann R, Brun ME, Senner F, et al. 2008. Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model. Drug Metab. Dispos. 36:2434-44
84. Poirier A, Funk C, Scherrmann JM, Lave T. 2009. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Mol. Pharm. 6:1716-33
85. Soars MG, Webborn PJ, Riley RJ. 2009. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry. Mol. Pharm. 6:1662-77
86. Bolger MB, Lukacova V, Woltosz WS. 2009. Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine. AAPS J. 11:353-63
87. Yang JS, Jamei M, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. 2007. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab. 8:676-84 (Pubitemid 47578116)
88. Gut model. Drug Metab. Rev. 40:92-93
89. Gertz M, Harrison A, Houston JB, Galetin A. 2010. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab. Dispos. 38:1147-58
90. g model and empirical scaling factor. Drug Metab. Dispos. 38:1230-37
91. Hisaka A, Ohno Y, Yamamoto T, Suzuki H. 2010. Theoretical considerations on quantitative prediction of drug-drug interactions. Drug Metab. Pharmacokinet. 25:48-61
92. Kusuhara H, Sugiyama Y. 2009. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab. Pharmacokinet. 24:37-52
93. Pelekis M, Poulin P, Krishnan K. 1995. An approach for incorporating tissue composition data into physiologically based pharmacokinetic models. Toxicol. Ind. Health 11:511-22 (Pubitemid 26067888)
94. Poulin P, Theil FP. 2000. A priori prediction of tissue: plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J. Pharm. Sci. 89:16-35 (Pubitemid 30080151)
95. Berezhkovskiy LM. 2004. Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics. J. Pharm. Sci. 93:364-74 (Pubitemid 38174258)
96. Rodgers T, Leahy D, Rowland M. 2005. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. J. Pharm. Sci. 94:1259-76 (Pubitemid 40904190)
97. Rodgers T, Rowland M. 2007. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm. Res. 24:918-33 (Pubitemid 46675393)
98. Poulin P, Theil FP. 2009. Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J. Pharm. Sci. 98:4941-61
99. Rodgers T, Rowland M. 2006. Mechanistic prediction of volume of distribution in rat and human. Drug Metab. Rev. 38:83 (Abstr.)
100. TM as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur. J. Pharm. Sci. 27:91-99 (Pubitemid 41728259)
101. Wei H, Dalton C, Di Maso M, Kanfer I, Lobenberg R. 2008. Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption. Eur. J. Pharm. Biopharm. 69:1046-56
102. Lobenberg R, Kramer J, Shah VP, Amidon GL, Dressman JB. 2000. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm. Res. 17:439-44 (Pubitemid 30395299)
103. Okumu A, Di Maso M, Lobenberg R. 2008. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug. Pharm. Res. 25:2778-85
104. Jones HM, Parrott N, Ohlenbusch G, Lave T. 2006. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modeling. Clin. Pharmacokinet. 45:1213-26 (Pubitemid 44904824)
105. Kimura T, Higaki K. 2002. Gastrointestinal transit and drug absorption. Biol. Pharm. Bull. 25:149-64 (Pubitemid 39592096)
106. Parrott N, Lukacova V, Fraczkiewicz G, Bolger MB. 2009. Predicting pharmacokinetics of drugs using physiologically based modeling-application to food effects. AAPS J. 11:45-53
107. Lukacova V, Woltosz WS, Bolger MB. 2009. Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data. AAPS J. 11:323-34
108. Tubic M, Wagner D, Spahn-Langguth H, Bolger MB, Langguth P. 2006. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm. Res. 23:1712-20 (Pubitemid 44200533)
109. Badhan R, Penny J, Galetin A, Houston JB. 2009. Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. J. Pharm. Sci. 98:2180-97
110. Willmann S, Edginton AN, Kleine-Besten M, Jantratid E, Thelen K, Dressman JB. 2009. Whole-body physiologically based pharmacokinetic population modeling of oral drug administration: inter-individual variability of cimetidine absorption. J. Pharm. Pharmacol. 61:891-99
111. Tubic-Grozdanis M, Bolger MB, Langguth P. 2008. Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds. AAPS J. 10:213-26
112. TM to justify a biowaiver for etoricoxib solid oral drug products. Eur. J. Pharm. Biopharm. 72:91-98
113. Kovacevic I, Parojcic J, Homsek I, Tubic-Grozdanis M, Langguth P. 2009. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol. Pharm. 6:40-47
114. Allan G, Davis J, Dickins M, Gardner I, Jenkins T, et al. 2008. Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man. Xenobiotica 38:620-40 (Pubitemid 351882978)
115. Gibson CR, Bergman A, Lu P, Kesisoglou F, Denney WS, Mulrooney E. 2009. Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modeling. Xenobiotica 39:637-48
116. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, et al. 2008. New era in drug interaction evaluation: U.S. Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol. 48:662-70 (Pubitemid 351713150)
117. Kelly CM, Juurlink DN, GomesT,Duong-HuaM,Pritchard KI,etal. 2010. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Br. Med. J. 340:c693
118. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, et al. 2009. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Can. Med. Assoc. J. 180:713-18
119. Tucker GT. 1992. The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int. J. Clin. Pharmacol. Ther. Toxicol. 30:550-53 (Pubitemid 23001983)
120. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. 1998. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol. Rev. 50:387-412
121. Peck CC, Temple R, Collins JM. 1993. Understanding consequences of concurrent therapies. J. Am. Med. Assoc. 269:1550-52 (Pubitemid 23086419)
122. Rowland M, Matin SB. 1973. Kinetics of drug-drug interactions. J. Pharmacokinet. Biopharm. 1:553-68
123. Wang YH, Jones DR, Hall SD. 2004. Prediction of cytochrome P450 3A inhibition by verapamil enan-tiomers and their metabolites. Drug Metab. Dispos. 32:259-66 (Pubitemid 38176944)
124. Rostami-Hodjegan A, Tucker GT. 2004. 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov. Today Tech. 1:441-48 (Pubitemid 40186348)
125. Galetin A, Burt H, Gibbons L, Houston JB. 2006. Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab. Dispos. 34:166-75 (Pubitemid 43042658)
126. Mayhew BS, Jones DR, Hall SD. 2000. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos. 28:1031-37 (Pubitemid 30660356)
127. Almond LM, Yang J, Jamei M, Tucker GT, Rostami-Hodjegan A. 2009. Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr. Drug Metab. 10:420-32
128. Kato M, Chiba K, Horikawa M, Sugiyama Y. 2005. The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab. Phar-macokinet. 20:236-43
129. Shou M, Hayashi M, Pan Y, Xu Y, Morrissey K, et al. 2008. Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab. Dispos. 36:2355-70
130. Ohno Y, Hisaka A, Ueno M, Suzuki H. 2008. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin. Pharmacokinet. 47:669-80
131. KozawaM, HonmaM, Suzuki H. 2009. Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay. DrugMetab. Dispos. 37:1234-41
132. Yang J, LiaoM, Shou M, Jamei M, Rowland-Yeo K, et al. 2008. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr. Drug Metab. 9:384-94
133. Van LM, Heydari A, Yang J, Hargreaves J, Rowland-Yeo K, et al. 2006. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy). J. Psychopharmacol. 20:834-41 (Pubitemid 44622749)
134. Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, et al. 2006. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr. DrugMetab. 7:315-34
135. Shou M. 2005. Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data. Curr. Opin. Drug Discov. Dev. 8:66-77 (Pubitemid 40116332)
136. Obach RS, Lombardo F, Waters NJ. 2008. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab. Dispos. 36:1385-405 (Pubitemid 351929323)
137. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. 2006. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther. 316:336-48 (Pubitemid 41832613)
138. Grime K, Riley RJ. 2006. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr. DrugMetab. 7:251-64
139. Hyland R, DickinsM, Collins C, Jones H, Jones B. 2008. Maraviroc: in vitro assessment of drug-drug interaction potential. Br. J. Clin. Pharmacol. 66:498-507
140. Xu L, Chen Y, Pan Y, Skiles GL, Shou M. 2009. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator. DrugMetab. Dispos. 37:2330-39
141. Youdim KA, Zayed A, Dickins M, Phipps A, Griffiths M, et al. 2008. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br. J. Clin. Pharmacol. 65:680-92 (Pubitemid 351535079)
142. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, et al. 2009. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. DrugMetab. Dispos. 37:1658-66
143. Einolf HJ. 2007. Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37:1257-94 (Pubitemid 350035530)
144. Gandelman K, Zhu T, Fahmi OA, Glue P, Lian K, et al. 2010. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J. Clin. Pharmacol. In press, doi:10.1177/0091270010366445
145. Shitara Y, Sato H, Sugiyama Y. 2005. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 45:689-723 (Pubitemid 40261822)
146. Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, et al. 2008. The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm. Res. 25:1891-901
147. Huang SM, Zhao H, Lee JI, Reynolds K, Zhang L, et al. 2010. Therapeutic protein-drug interactions and implications for drug development. Clin. Pharmacol. Ther. 87:497-503
148. Jamei M, Marciniak S, Feng K, Barnett A, Tucker GT, Rostami-Hodjegan A. 2009. The Simcyp® population-based ADME simulator. Expert Opin. DrugMetab. Toxicol. 5:211-23
149. Vossen M, Sevestre M, Niederalt C, Jang IJ, Willmann S, Edginton AN. 2007. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theor. Biol. Med. Model. 4:13
150. Fenneteau F, Poulin P, Nekka F. 2010. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J. Pharm. Sci. 99:486-514
151. Wang YH. 2010. Confidence assessment of the Simcyp time-based approach and a static mathematic model in predicting clinical drug-drug interactions for mechanistic-based CYP3A inhibitors.Drug Metab. Dispos. 38:1094-104
152. Perdaems N, Blasco H, Vinson C, Chenel M, Whalley S, et al. 2010. Predictions of metabolic drug-drug interactions using physiologically based modeling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin. Pharmacokinet. 49:239-58
153. Yang J, Kjellsson M, Rostami-Hodjegan A, Tucker GT. 2003. The effects of dose staggering on metabolic drug-drug interactions. Eur. J. Pharm. Sci. 20:223-32 (Pubitemid 37205216)
154. Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, et al. 2009. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J. Clin. Pharmacol. 49:351-59
155. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, Nettleton D. 2008. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab. Dispos. 36:1698-708
156. Zhang X, Quinney SK, Gorski JC, Jones DR, Hall SD. 2009. Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab. Dispos. 37:1587-97
157. Rowland-Yeo K, Jamei M, Yang J, Tucker GT, Rostami-Hodjegan A. 2010. Physiologically based mechanistic modeling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-the effect of diltiazem on the time-course of exposure to triazolam. Eur. J. Pharm. Sci. 39:298-309
158. Chien JY, Mohutsky MA, Wrighton SA. 2003. Physiological approaches to the prediction of drug-drug interactions in study populations. Curr. Drug Metab. 4:347-56 (Pubitemid 37279360)
159. Polasek TM, Sadagopal JS, Elliot DJ, Miners JO. 2010. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. Eur. J. Clin. Pharmacol. 66:275-83
160. Tucker GT, Houston JB, Huang SM. 2001. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm. Res. 18:1071-80 (Pubitemid 32900389)
161. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, et al. 2003. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J. Clin. Pharmacol. 43:443-69 (Pubitemid 36506147)
162. Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, et al. 2009. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab. Dispos. 37:1355-70
163. Chu V, Einolf HJ, Evers R, Kumar G, Moore D, et al. 2009. In vitro and in vivo induction of cy-tochrome P450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of America perspective. Drug Metab. Dispos. 37:1339-54
164. Zhang L, Zhang YD, Zhao P, Huang SM. 2009. Predicting drug-drug interactions: an FDA perspective. AAPS J. 11:300-6
165. Zhang L, Zhang Y, Huang SM. 2009. Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. Mol. Pharm. 6:1766-74
166. Zhang L, Reynolds KS, Zhao P, Huang SM. 2010. Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol. Appl. Pharmacol. 243:134-45
167. 2008. EMEA workshop on modeling in paediatric medicines. http://www.ema.europa.eu/meetings/conferences/1415apr08.htm
168. Manolis E, Pons G. 2009. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. Br. J. Clin. Pharmacol. 68:493-501
169. HolfordN. 2010. Dosing in children. Clin. Pharmacol. Ther. 87:367-70
170. Johnson TN, Tucker GT, Tanner MS, Rostami-HodjeganA. 2005. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl. 11:1481-93 (Pubitemid 43072624)
171. Johnson TN, Rostami-Hodjegan A, Tucker GT. 2006. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 45:931-56 (Pubitemid 44299829)
172. Edginton AN, Schmitt W, Voith B, Willmann S. 2006. A mechanistic approach for the scaling of clearance in children. Clin. Pharmacokinet. 45:683-704 (Pubitemid 43990570)
173. Bjorkman S. 2005. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modeling: theophylline and midazolam as model drugs. Br. J. Clin. Pharmacol. 59:691-704 (Pubitemid 40835503)
174. EdgintonAN, Schmitt W, Willmann S. 2006. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin. Pharmacokinet. 45:1013-34 (Pubitemid 44436004)
175. Butler JM, Begg EJ. 2008. Free drug metabolic clearance in elderly people. Clin. Pharmacokinet. 47:297-321 (Pubitemid 351508117)
176. Kusuma M, Maeda K, Chiba K, Aoyama A, Sugiyama Y. 2008. Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data. Pharm. Res. 26:822-35
177. Dickinson GL, Lennard MS, Tucker GT, Rostami-Hodjegan A. 2007. The use of mechanistic DM-PK-PD modeling to assess the power of pharmacogenetic studies-CYP2C9 and warfarin as an example. Br. J. Clin. Pharmacol. 64:14-26 (Pubitemid 46934416)
178. Jornil J, Jensen KG, Larsen F, Linnet K. 2010. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. DrugMetab. Dispos. 38:376-85
179. Edginton AN, Willmann S. 2008. Physiology-based simulation of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin. Pharmacokinet. 47:743-52
180. Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. 2010. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin. Pharmacokinet. 49:189-206
181. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). 2005. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. http://www.emea.europa.eu/ pdfs/human/ewp/233902en.pdf
182. Nolin TD, Naud J, Leblond FA, Pichette V. 2008. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin. Pharmacol. Ther. 83:898-903 (Pubitemid 351704931)
183. Schmith VD, FossJF. 2010. Inflammation: planning for a source of pharmacokinetic/pharmacodynamic variability in translational studies. Clin. Pharmacol. Ther. 87:488-91
184. Hanley MJ, Abernethy DR, Greenblatt DJ. 2010. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet. 49:71-87
185. Clewell HJ III, Andersen ME, Wills RJ, Latriano L. 1997. A physiologically based pharmacokinetic model for retinoic acid and its metabolites. J. Am. Acad. Dermatol. 36:S77-85 (Pubitemid 27132004)
186. Ghosh TK. 2000. Clinical pharmacology and biopharmaceutics review: NDA 21-108, 0.02% Tretinoin Emollient Cream (RENOVA®). http://www.accessdata. fda.gov/drugsatfda-docs/nda/2000/21-108-Renova-BioPharmr.pdf
187. Huang SM, Lesko LJ. 2009. Authors' response. J. Clin. Pharmacol. 49:370
188. Duan JZ, Jackson AJ, Zhao P. 2010. Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach. J. Clin. Pharmacol. In press, doi:10.1177/0091270010377200
189. Zhao P, Zhang L, Huang SM. 2010. Complex drug interactions: significance and evaluation. In Enzyme-and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges, ed. KS Pang, AD Rodrigues, RM Peter, pp. 667-692. New York: Springer. 746 pp.
190. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KLR, et al. 2010. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9:215-36
191. U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2005. Guidance for industry: clinical lactation studies-study design, data analysis, and recommendations for labeling. http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/ucm127505.pdf
192. Lionberger R. 2009. Regulatory applications of modeling and simulations at FDA. http://www. thehamner.org/docs/pbpk-09/Day1.Lionberger.pdf
193. Lam TN, Hunt CA. 2010. Mechanistic insight from in silico pharmacokinetic experiments: roles of P-glycoprotein, CYP3A4 enzymes, and microenvironments. J. Pharmacol. Exp. Ther. 332:398-412
194. Johnson TN, Kerbusch T, Jones B, Tucker GT, Rostami-Hodjegan A, Milligan PA. 2009. Assessing the efficiency of mixed effects modeling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power. Pharm. Stat. 8:186-202
195. Fanta S, Jonsson S, Backman JT, Karlsson MO, Hoppu K. 2007. Developmental pharmacokinetics of ciclosporin-a population pharmacokinetic study in paediatric renal transplant candidates. Br. J. Clin. Pharmacol. 64:772-84 (Pubitemid 350222065)
196. Schmitt W, Willmann S. 2004. Physiology-based pharmacokinetic modeling: ready to be used. Drug Discov. Today Tech. 1:449-56 (Pubitemid 40186349)
197. Jones HM, Parrott N, Jorga K, Lave T. 2006. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet. 45:511-42
198. Clewell HJ III, Reddy MB, Lave T, Andersen ME. 2008. Physiologically based pharmacokinetic modeling. In Preclinical Development Handbook: ADME and Biopharmaceutical Properties, ed. SC Gad, pp. 1167-228. Hoboken, NJ: Wiley. 1329 pp.